Source:http://linkedlifedata.com/resource/pubmed/id/19289855
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
21
|
| pubmed:dateCreated |
2009-5-27
|
| pubmed:abstractText |
Mutations of the CCAAT/enhancer binding protein alpha (CEBPA) gene have been associated with a favorable outcome in patients with acute myeloid leukemia (AML), but mainly in those with a normal karyotype. Here, we analyzed the impact of associated cytogenetic abnormalities or bad-prognosis fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in 53 patients with CEBPA(+) de novo AML treated in the Acute Leukemia French Association trials. We found that only those with a normal karyotype and no FLT3-ITD displayed the expected favorable outcome. In this context, relapse-free, disease-free, and overall survival were significantly longer than in corresponding patients without the CEBPA mutation (P = .035, .016, and .047, respectively). This was not observed in the context of an abnormal karyotype or associated FLT3-ITD. Furthermore, after adjustment on age, trial, and mutation type, these features were independently predictive of shorter overall survival in the subset of patients with CEBPA(+) AML (multivariate hazard ratio = 2.7; 95% confidence interval, 1.08-6.7; and 2.9; 95% confidence interval, 1.01-8.2; with P = .034 and .05, for abnormal karyotype and FLT3-ITD, respectively).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:BastardChristianC,
pubmed-author:BoisselNicolasN,
pubmed-author:CastaigneSylvieS,
pubmed-author:DombretHervéH,
pubmed-author:GachardNathalieN,
pubmed-author:GardinClaudeC,
pubmed-author:NaguibDinaD,
pubmed-author:NibourelOlivierO,
pubmed-author:PautasCécileC,
pubmed-author:PreudhommeClaudeC,
pubmed-author:RemanOumedalyO,
pubmed-author:RennevilleAlineA,
pubmed-author:TerréChristineC,
pubmed-author:ThomasXavierX,
pubmed-author:de BottonStéphaneS
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
21
|
| pubmed:volume |
113
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5090-3
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:19289855-Adolescent,
pubmed-meshheading:19289855-Adult,
pubmed-meshheading:19289855-Aged,
pubmed-meshheading:19289855-CCAAT-Enhancer-Binding Protein-alpha,
pubmed-meshheading:19289855-Chromosome Aberrations,
pubmed-meshheading:19289855-Disease-Free Survival,
pubmed-meshheading:19289855-Female,
pubmed-meshheading:19289855-Gene Duplication,
pubmed-meshheading:19289855-Humans,
pubmed-meshheading:19289855-Leukemia, Myeloid, Acute,
pubmed-meshheading:19289855-Male,
pubmed-meshheading:19289855-Middle Aged,
pubmed-meshheading:19289855-Mutation,
pubmed-meshheading:19289855-Prognosis,
pubmed-meshheading:19289855-Recurrence,
pubmed-meshheading:19289855-Survival Rate,
pubmed-meshheading:19289855-Treatment Outcome,
pubmed-meshheading:19289855-Young Adult,
pubmed-meshheading:19289855-fms-Like Tyrosine Kinase 3
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.
|
| pubmed:affiliation |
Department of Hematology, Hôpital Claude Huriez, Lille, France.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|